Related Experiment Videos
Molecular targeting for malignant gliomas (Review).
Yasuko Kondo1, Emporia F Hollingsworth, Seiji Kondo
1Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
International Journal of Oncology
|April 7, 2004
Summary
Malignant gliomas are resistant to standard treatments. Targeting specific molecules like EGFR and pathways such as PI3K/Akt/mTOR offers a promising approach for effective cancer therapy with reduced side effects.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer genetics
Background:
- Malignant gliomas exhibit rapid invasion and resistance to conventional therapies (radiation, chemotherapy).
- Advances in molecular techniques enable detailed profiling of glioma tissues.
Purpose of the Study:
- To review targeted therapeutic strategies for malignant gliomas.
- To identify key molecular targets based on glioblastoma tissue profiles.
Main Methods:
- Literature review of genetic and molecular techniques.
- Analysis of molecules closely related to glioblastoma tissues.
- Examination of targeted therapies for identified molecules.
Main Results:
- Key target molecules identified include EGFR, PTEN, and telomerase.
- Signal pathways like Ras/Raf/MAPK and PI3K/Akt/mTOR are crucial targets.
- Targeted therapies aim to selectively eliminate tumor cells.
Conclusions:
- Targeting specific molecular profiles of malignant gliomas presents a viable therapeutic strategy.
- Precision medicine approaches may enhance treatment efficacy and minimize damage to normal cells.